查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609583

GLP-1受体促效剂市场规模、份额和趋势分析报告：按产品、按应用、按给药途径、按地区和细分市场预测，2025-2030年

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Ozempic, Zepbound), By Application (Diabetes, Obesity), By Route Of Administration (Parenteral, Oral), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

GLP-1受体促效剂市场成长与趋势

Grand View Research, Inc.最新报告显示，预计到2030年全球GLP-1受体促效剂市场规模将达到1,567.1亿美元，2025年至2030年复合年增长率为17.46%。

强大的产品平臺和配方进步正在推动市场发展。此外，新的创新产品正在为市场注入活力。 2019年9月，第一个也是唯一一个口服GLP-1类似物Rybelsus获得美国FDA核准，用于改善第二型糖尿病患者的血糖控制。该药物是诺和诺德开发的基于Semaglutide的产品，目前正在接受欧洲药品管理局（EMA）和药品和医疗设备管理局（PMDA）的审查。获得核准后，市场可能在预测期内显着增长。

此外，製药公司正致力于研究合作以开发新的 GLP-1 产品。例如，2018年9月，礼来公司与中外製药有限公司就OWL833签订了授权合约。 OWL833是中外製药公司专有的口服GLP-1促效剂候选药物，根据协议，礼来公司将获得全球商业化和开发权。

两家公司目前都在寻求地域扩张以增加销售额。诺和诺德正在透过投资北卡罗来纳州的製造业务来扩大其业务。该公司约占GLP-1受体促效剂市场占有率的50.0%，预计在预测期内将主导市场。此外，2018年7月，赛诺菲在中国投资约7,410万美元建立研发中心，以加强其全球影响力。

两家公司也致力于获得美国FDA 以及欧洲、中东和非洲当局对肥胖和主要不良心血管事件等其他适应症的核准，以改善现有产品的生命週期。例如，2020年1月，诺和诺德的Ozempic获得美国FDA核准，用于治疗第二型糖尿病患者的主要不利事件（MACE）。

GLP-1 受体促效剂市场报告亮点

  • Ozempic 细分市场占据主导地位，到 2024 年，其份额将达到 34.17%。 Ozempic 是美国FDA核准的用于治疗成人 2 型糖尿病的组合药物的品牌名称。
  • Zepbound 预计 2025 年至 2030 年将以大幅复合年增长率成长。这种增长是由于全球药物的核准以及由于其高功效和耐受性而产生的高需求。
  • 2 型糖尿病细分市场预计将在 2024 年占据市场主导地位，在预测期内复合年增长率为 17.06%。
  • 2024年，注射剂领域占最大份额，预计2025-2030年复合年增长率为17.42%。
  • 医院药局板块占比最大，2024年将达55.09%。医院药局的发展促进了多个医疗部门的整合，增加了糖尿病和肥胖症咨询的住院人数，并提高了客户获取 GLP-1 药物的便利性。
  • 2024年北美GLP-1受体促效剂市场占77.72%。北美GLP-1受体促效剂市场由Liraglutide（Victoza）、Dulaglutide（Turicity）、Exenatide（Byetta/Vydureon）和Semaglutide（Ozempic）等现有品牌主导。
  • 亚太地区GLP-1受体促效剂市场预计将成为全球成长最快的市场。该地区不断增长的医疗保健行业、庞大的目标人口以及未满足的需求预计将提供巨大的成长潜力。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章 GLP-1 受体促效剂市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • GLP-1 受体促效剂市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 价格分析
  • 管道分析
  • 专利到期分析

第四章 GLP-1受体促效剂市场：依产品估算与趋势分析

  • 全球 GLP-1 受体促效剂市场：产品仪表板
  • 全球 GLP-1 受体促效剂市场：产品变异分析
  • 臭氧
  • 卢贝尔苏斯
  • 特鲁利西蒂
  • 萨克森达
  • 韦戈维
  • 维克托扎
  • 蒙札罗
  • 泽普绑定
  • 其他的

第五章 GLP-1受体促效剂市场：应用、估算与趋势分析

  • 全球 GLP-1 受体促效剂市场：应用仪表板
  • 全球GLP-1受体促效剂市场：应用变化分析
  • 2型糖尿病
  • 肥胖

第六章 GLP-1受体促效剂市场：依给药途径估计与趋势分析

  • 全球 GLP-1 受体促效剂市场：给药途径仪表板
  • 全球GLP-1受体促效剂市场：给药途径变化分析
  • 胃肠外的
  • 口服

第7章GLP-1受体促效剂市场：依通路估算与趋势分析

  • 全球 GLP-1 受体促效剂市场：通路仪表板
  • 全球GLP-1受体促效剂市场：通路波动分析
  • 医院药房
  • 零售药房
  • 网路药房

第 8 章 GLP-1促效剂市场：按产品、应用、给药途径和分销管道分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 公司/竞争对手分类
  • 参与者概览
  • Financial Overview
  • 2024 年企业市场占有率分析
  • 策略规划
  • 公司简介
    • Eli Lilly and Company.
    • Sanofi
    • Novo Nordisk A/S
    • AstraZeneca.
Product Code: GVR-4-68038-694-3

GLP-1 Receptor Agonist Market Growth & Trends:

The global GLP-1 receptor agonist market size is expected to reach USD 156.71 billion by 2030, expanding at a CAGR of 17.46% from 2025 to 2030, according to a new report by Grand View Research, Inc. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.

Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai's proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.

The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.

The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA, and others for the existing products to increase their life cycle. For instance, in January 2020, Novo Nordisk received the U.S. FDA approval for Ozempic for Major Adverse Cardiovascular Events (MACE) in type 2 diabetes patients.

GLP-1 Receptor Agonist Market Report Highlights:

  • The ozempic segment dominated the market and accounted for a share of 34.17% in 2024. Ozempic is a brand-name U.S. FDA-approved prescription drug used to treat adults with type 2 diabetes.
  • Zepbound is expected to grow at a significant CAGR from 2025 to 2030. This growth can be attributed to its worldwide approval of a drug and high demand due to its high efficacy and tolerability.
  • The type 2 diabetes mellitus segment dominated the market in 2024 and is expected to grow at a CAGR of 17.06% over the forecast period.
  • The parenteral segment held the largest share in 2024 and is expected to grow at a CAGR of 17.42% from 2025 to 2030.
  • The hospital pharmacies segment held the largest share of 55.09% in 2024. The growth of hospital pharmacies has facilitated the integration of several healthcare components, increased inpatient visits for diabetes and obesity consultations, and improved customer convenience in acquiring GLP-1 medications.
  • North America GLP-1 receptor agonist market accounted for a 77.72% share in 2024. Established brands including liraglutide (Victoza), dulaglutide (Trulicity), exenatide (Byetta/Bydureon), and semaglutide (Ozempic) dominate the GLP-1 receptor agonist market in North America.
  • Asia Pacific GLP-1 receptor agonists market is anticipated to witness the fastest growth in the global market. The region's growing healthcare sector, sizable target population, and high unmet clinical needs are some factors projected to provide significant growth potential.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Application Outlook
    • 2.2.2. Route of Administration and Distribution Channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases such as diabetes and obesity
      • 3.2.1.2. Increasing R&D activities for developing novel therapeutics
      • 3.2.1.3. Formulation advancements of oral GLP-1 receptor agonists
      • 3.2.1.4. Increasing awareness about diagnosis and treatment options for diabetes
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Product failure
      • 3.2.2.2. Patent expiry of blockbuster drugs during the forecast period
  • 3.3. GLP-1 Receptor Agonist Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis
  • 3.5. Pipeline Analysis
  • 3.6. Patent Expiry Analysis

Chapter 4. GLP-1 Receptor Agonist Market: Product Estimates & Trend Analysis

  • 4.1. Global GLP-1 Receptor Agonist Market: Product Dashboard
  • 4.2. Global GLP-1 Receptor Agonist Market: Product Movement Analysis
  • 4.3. Ozempic
    • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4. Rybelsus
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Trulicity
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Saxenda
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Wegovy
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Victoza
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Mounjaro
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Zepbound
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. GLP-1 Receptor Agonist Market: Application Estimates & Trend Analysis

  • 5.1. Global GLP-1 Receptor Agonist Market: Application Dashboard
  • 5.2. Global GLP-1 Receptor Agonist Market: Application Movement Analysis
  • 5.3. Type 2 Diabetes Mellitus
    • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Obesity
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global GLP-1 Receptor Agonist Market: Route of Administration Dashboard
  • 6.2. Global GLP-1 Receptor Agonist Market: Route of Administration Movement Analysis
  • 6.3. Parenteral
    • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Global GLP-1 Receptor Agonist Market: Distribution Channel Dashboard
  • 7.2. Global GLP-1 Receptor Agonist Market: Distribution Channel Movement Analysis
  • 7.3. Hospital Pharmacies
    • 7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Online Pharmacies
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis By Product, Application, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Denmark
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Norway
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Participant Overview
  • 9.3. Financial Overview
  • 9.4. Product Benchmarking
  • 9.5. Company Market Share Analysis, 2024
  • 9.6. Strategy Mapping
  • 9.7. Company Profiles
    • 9.7.1. Eli Lilly and Company.
      • 9.7.1.1. Company overview
      • 9.7.1.2. Financial performance
      • 9.7.1.3. benchmarking
      • 9.7.1.4. Strategic initiatives
    • 9.7.2. Sanofi
      • 9.7.2.1. Company overview
      • 9.7.2.2. Financial performance
      • 9.7.2.3. benchmarking
      • 9.7.2.4. Strategic initiatives
    • 9.7.3. Novo Nordisk A/S
      • 9.7.3.1. Company overview
      • 9.7.3.2. Financial performance
      • 9.7.3.3. benchmarking
      • 9.7.3.4. Strategic initiatives
      • 9.7.3.5.
    • 9.7.4. AstraZeneca.
      • 9.7.4.1. Company overview
      • 9.7.4.2. Financial performance
      • 9.7.4.3. benchmarking
      • 9.7.4.4. Strategic initiatives

List of Tables

  • Table 1 Index of Tables
  • Table 2 List of key distributors and channel partners
  • Table 3 List of key emerging companies'/technology disruptors/innovators
  • Table 4 North America GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
  • Table 5 North America GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 6 North America GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 7 North America GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 North America GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 U.S. GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 10 U.S. GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 U.S.GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 14 Canada GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 15 Canada GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Canada GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 18 Mexico GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 19 Mexico GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Mexico GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Europe GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
  • Table 22 Europe GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 23 Europe GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 24 Europe GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 Europe GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Germany GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 27 Germany GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 28 Germany GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Germany GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 UK GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 31 UK GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 UK GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 UK GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 France GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 35 France GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 36 France GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 France GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Italy GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 39 Italy GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 40 Spain GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 Italy GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Spain GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 43 Spain GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 44 Denmark GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 Spain GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Denmark GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 47 Denmark GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 48 Denmark GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Denmark GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Sweden GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 Sweden GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 52 Sweden GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 Sweden GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Norway GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 55 Norway GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 56 Norway GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 Norway GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Japan GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 64 Japan GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Japan GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 Japan GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 China GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 68 China GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 69 China GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 China GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 India GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 72 India GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 73 India GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 India GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 Australia GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 76 Australia GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 77 Australia GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Australia GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 South Korea GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 80 South Korea GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 81 South Korea GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 South Korea GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 Thailand GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 84 Thailand GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 85 Thailand GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 Thailand GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 Latin America GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
  • Table 88 Latin America GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 89 Latin America GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 90 Latin America GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 Latin America GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Brazil GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 93 Brazil GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 94 Brazil GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 95 Brazil GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 96 Argentina GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 97 Argentina GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 98 Argentina GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 99 Argentina GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 100 MEA GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
  • Table 101 MEA GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 102 MEA GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 103 South Africa GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 104 MEA GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 105 South Africa GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 106 South Africa GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 107 South Africa GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 108 South Africa GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 113 UAE GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 114 UAE GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 115 UAE GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 116 UAE GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 117 Kuwait GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
  • Table 118 Kuwait GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Table 119 Kuwait GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 120 Kuwait GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 GLP-1 Receptor Agonist Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 GLP-1 Receptor Agonist Market snapshot (2024)
  • Fig. 9 GLP-1 Receptor Agonist Market: Segment snapshot (2024)
  • Fig. 10 Competitive Insights (2024)
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 GLP-1 Receptor Agonist Market driver impact
  • Fig. 14 GLP-1 Receptor Agonist Market restraint impact
  • Fig. 15 Porter's Five Forces Analysis
  • Fig. 16 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig. 17 Strategic alliance analysis
  • Fig. 18 Recent developments & impact analysis, by key market participants
  • Fig. 19 Key company market share analysis, 2024
  • Fig. 20 Company market position analysis
  • Fig. 21 Definition and scope, by product
  • Fig. 22 Product market share analysis, 2024 & 2030
  • Fig. 23 Segment dashboard
  • Fig. 24 Global GLP-1 Receptor Agonist Market, by product, 2018 - 2030 (USD Million)
  • Fig. 25 Ozempic market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 26 Rybelsus market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 27 Trulicity market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 28 Saxenda market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 29 Mounjaro market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 30 Victoza market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 31 Zepbound market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 32 Wegovy market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 33 Other market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 34 Definition and scope, by Application
  • Fig. 35 Application market share analysis, 2024 & 2030
  • Fig. 36 Segment dashboard.
  • Fig. 37 Global GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
  • Fig. 38 Type 2 diabetes mellitus market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 39 Obesity market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 40 Definition and scope by route of administration
  • Fig. 41 Route of administration market share analysis, 2024 & 2030
  • Fig. 42 Segment dashboard.
  • Fig. 43 Global GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Fig. 44 Parenteral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 45 Oral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 46 Definition and scope, by distribution channel
  • Fig. 47 Distribution channel market share analysis, 2024 & 2030
  • Fig. 48 Segment dashboard.
  • Fig. 49 Global GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Fig. 50 Hospital pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 51 Retail pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 52 Online pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 53 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 54 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 55 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 56 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 57 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 58 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 59 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 60 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 61 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 62 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 63 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 64 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 65 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 66 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 67 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 68 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 69 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 70 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 71 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 72 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 73 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 74 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 75 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million))
  • Fig. 76 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 77 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 78 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 79 UAE market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 80 Kuwait market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)